BioCentury
ARTICLE | Finance

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

With backing from its syndicate’s five investors, Renovacor is eyeing an IND submission

August 14, 2019 11:00 AM UTC

With nothing left to prove in an academic setting, five-year-old Renovacor has attracted an $11 million series A round designed to complete preclinical testing of its gene therapy for a rare form of dilated cardiomyopathy.

Novartis Venture Fund, Broadview Ventures and BioAdvance led the round, joined by New Leaf Venture Partners and Innogest Capital...

BCIQ Company Profiles

Renovacor Inc.